Lipiodolization for unresectable hepatocellular carcinoma: an analysis of 205 patients using univariate and multivariate analysis.
Since 1982 we have developed and successfully performed lipiodolization on 205 patients with unresectable hepatocellular carcinoma. The 1-, 2-, 3-, 4-, and 5-year survival rates were 55.6%, 31.7%, 16.3%, 8.7%, and 2.9%, respectively, while the median survival was 413 days, and 20 patients survived longer than 3 years after the first lipiodolization. Our study demonstrated that the factors for a comparatively good prognosis were as follows: patient older than 50 years, nodular type hepatocellular carcinoma < 5 cm in diameter, negative tumor invasion of portal vein, < 10 intrahepatic metastases, serum alpha-fetoprotein level < 400 ng/ml, and Okuda stage I. Lipiodolization did not cure hepatocellular carcinoma. It did, however, in this study, achieve a prolongation of the patient's survival.
Urata
K
K
Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Matsumata
T
T
Kamakura
T
T
Hasuo
K
K
Sugimachi
K
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D007459:Iodized Oil / Q000008:administration & dosage / Q000627:therapeutic use*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome
D007459:Iodized Oil